In 2012, Pignatelli et al. [204] showed that atorvastatin treatment in patients with polygenic hypercholesterolemia exerts anti-oxidant properties by inhibition of NADPH oxidase 2 (Nox2), which is one of the reactive oxygen species (ROS) generating enzyme. Here, CYBB is linked to familial hypercholesterolemia.